Novo Nordisk Partners With OpenAI as AI Drug Discovery Gains Momentum

Novo Nordisk announced a strategic partnership with OpenAI to deploy advanced artificial intelligence across its operations, aiming to accelerate drug discovery and improve patient care outcomes. The collaboration will integrate OpenAI's AI capabilities across the full value chain, from early-stage research to manufacturing and commercial operations, with pilot programmes expected to roll out across research and development, manufacturing and commercial functions and full integration planned by the end of 2026.

The company said AI will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application. The partnership will also focus on improving efficiency in manufacturing, supply chains and corporate functions, and OpenAI will support workforce upskilling at Novo Nordisk, with a focus on enhancing AI literacy across its global teams. The company emphasised that the partnership includes strict data protection, governance and human oversight to ensure ethical and compliant use of AI technologies. The announcement builds on Novo Nordisk's existing investments in artificial intelligence through collaborations with technology partners and research organisations.

Novo Nordisk's president and CEO said the partnership is one important step in positioning the company to lead in the next era of healthcare, adding that integrating AI in everyday work gives the ability to analyse datasets at a scale previously impossible, identify patterns that could not be seen, and test hypotheses faster than ever. He said the move could significantly accelerate the discovery of new therapies, particularly for chronic conditions like obesity and diabetes, where unmet medical needs remain high. OpenAI's CEO said the collaboration reflects the growing role of artificial intelligence in life sciences, and that it will help accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.

The partnership reflects a broader shift in drug discovery, where AI is entering a defining phase and is being viewed through a more pragmatic lens by the pharmaceutical and biotechnology industry. Rather than replacing the entire drug development process, AI is increasingly recognized as a tool that helps overcome specific bottlenecks, including target identification, protein structure prediction, antibody design, developability assessment, clinical trial design, and patient stratification. Global pharmaceutical companies are adapting through mergers and acquisitions, strategic investments, and in-house platform development to improve R&D productivity. The key question is no longer whether AI should be used, but where it should be integrated, what data should be accumulated, and whether AI-generated candidates can successfully advance through preclinical and clinical development.

Global pharmaceutical companies are broadly taking two approaches: collaborating with specialized AI companies to accelerate early-stage drug discovery, and embedding AI across R&D operations to improve clinical development and decision-making. Sanofi has partnered with OpenAI and Formation Bio to develop AI-powered software for use throughout the drug development process. Eli Lilly has announced a collaboration with OpenAI to identify treatments for antimicrobial-resistant bacterial infections. Alphabet's Isomorphic Labs signed strategic research partnerships worth up to $3 billion with Lilly and Novartis and expanded its collaboration with Novartis last year. Genentech is working with Nvidia to enhance its AI-driven drug discovery platform, while AstraZeneca has partnered with Absci on AI-enabled antibody discovery. In February, Iambic Therapeutics announced a multi-year collaboration with Takeda, under which it will apply its AI drug discovery platform and wet-lab capabilities to support Takeda's small-molecule programs in oncology, gastrointestinal, and inflammatory diseases. AI-enabled drug discovery is no longer the exclusive domain of AI companies; global pharmaceutical firms increasingly use AI specialists as external research partners while retaining control over downstream development, manufacturing, clinical development, and commercialization.

The U.S. Food and Drug Administration is treating AI as a regulatory science issue spanning the entire drug development lifecycle. The agency has issued guidance stating that when AI generates data or information supporting regulatory decisions on drug safety, efficacy, or quality, its reliability should be evaluated based on its intended use, suggesting that AI is evolving beyond a research support tool into a component of regulatory submissions and R&D decision-making.

In India, the Union Health and Family Welfare Minister said AI-driven tools can accelerate drug discovery, shorten research timelines, and make research processes more cost-effective, thereby strengthening affordable healthcare delivery. Speaking at the launch of the SAHI (Secure AI for Health Initiative) and BODH (Benchmarking Open Data Platform for Health AI) during the India AI Impact Summit 2026, he said AI does not operate in isolation but thrives on strong digital infrastructure and high-quality data. He noted that India recognized this early and began laying its digital foundations nearly a decade ago, including the Digital India programme launched in 2015, and that interoperable systems have been enabled across platforms, with large-scale, consent-based health data frameworks being developed to empower citizens while ensuring data privacy and security.

Protein structure prediction and protein design remain among the technologies that have fueled expectations for AI-driven drug discovery. A protein's three-dimensional structure is fundamental to understanding its function, and because drugs exert their effects by binding to target proteins, understanding protein-drug interactions is critical for improving efficacy and selectivity.